{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:29:01Z","timestamp":1787887741261,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.<\/jats:p>","DOI":"10.1093\/pnasnexus\/pgad256","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:39:18Z","timestamp":1691102358000},"source":"Crossref","is-referenced-by-count":10,"title":["Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-5630","authenticated-orcid":false,"given":"Mark","family":"Dittmar","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania , 3450 Hamilton Walk Philadelphia, PA 19104 , USA"},{"name":"Department of Microbiology, University of Pennsylvania , 3450 Hamilton Walk Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanupriya","family":"Whig","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania , 3450 Hamilton Walk Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-8223","authenticated-orcid":false,"given":"Brinda","family":"Kamalia","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-4414","authenticated-orcid":false,"given":"Suganthi","family":"Suppiah","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention , 1600 Clifton Rd. Atlanta, GA 30329 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0812-8124","authenticated-orcid":false,"given":"Ludmila","family":"Perelygina","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention , 1600 Clifton Rd. Atlanta, GA 30329 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-1646","authenticated-orcid":false,"given":"Kathleen E","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Children's Hospital of Philadelphia , 3615 Civic Center Blvd., Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-8815","authenticated-orcid":false,"given":"David C","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-6610","authenticated-orcid":false,"given":"Sara","family":"Cherry","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania , 3450 Hamilton Walk Philadelphia, PA 19104 , USA"},{"name":"Department of Microbiology, University of Pennsylvania , 3450 Hamilton Walk Philadelphia, PA 19104 , USA"},{"name":"Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"2023092920103428000_pgad256-B1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1542\/pir.31.3.129","article-title":"Rubella","volume":"31","author":"Drutz","year":"2010","journal-title":"Pediatr Rev"},{"key":"2023092920103428000_pgad256-B2","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001817","article-title":"ICTV virus taxonomy profile: Matonaviridae 2022","volume":"103","author":"Mankertz","year":"2022","journal-title":"J Gen Virol"},{"key":"2023092920103428000_pgad256-B3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.siny.2007.01.017","article-title":"Rubella","volume":"12","author":"Best","year":"2007","journal-title":"Semin Fetal Neonatal Med"},{"key":"2023092920103428000_pgad256-B4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.15585\/mmwr.mm7106a2","article-title":"Progress toward rubella and congenital rubella syndrome control and elimination\u2014worldwide, 2012\u20132020","volume":"71","author":"Zimmerman","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023092920103428000_pgad256-B5","doi-asserted-by":"crossref","first-page":"e1412","DOI":"10.1016\/S2214-109X(22)00335-7","article-title":"Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study","volume":"10","author":"Winter","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2023092920103428000_pgad256-B6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jaci.2016.06.030","article-title":"Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies","volume":"138","author":"Perelygina","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2023092920103428000_pgad256-B7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jamadermatol.2022.0828","article-title":"Association of persistent rubella virus with idiopathic skin granulomas in clinically immunocompetent adults","volume":"158","author":"Wanat","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023092920103428000_pgad256-B8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/ACI.0000000000000694","article-title":"Rubella virus-associated chronic inflammation in primary immunodeficiency diseases","volume":"20","author":"Perelygina","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2023092920103428000_pgad256-B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008080","article-title":"Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies","volume":"15","author":"Perelygina","year":"2019","journal-title":"PLoS Pathog"},{"key":"2023092920103428000_pgad256-B10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10875-019-0589-0","article-title":"Outcomes for nitazoxanide treatment in a case series of patients with primary immunodeficiencies and rubella virus-associated granuloma","volume":"39","author":"Perelygina","year":"2019","journal-title":"J Clin Immunol"},{"key":"2023092920103428000_pgad256-B11","doi-asserted-by":"crossref","first-page":"e01201","DOI":"10.1128\/AAC.01201-19","article-title":"Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis","volume":"63","author":"Berliba","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092920103428000_pgad256-B12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.09.019","article-title":"Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency","volume":"147","author":"Perelygina","year":"2017","journal-title":"Antiviral Res"},{"key":"2023092920103428000_pgad256-B13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073014","article-title":"Persistent infection of human fetal endothelial cells with rubella virus","volume":"8","author":"Perelygina","year":"2013","journal-title":"PLoS One"},{"key":"2023092920103428000_pgad256-B14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.celrep.2016.12.068","article-title":"Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus","volume":"18","author":"Rausch","year":"2017","journal-title":"Cell Rep"},{"key":"2023092920103428000_pgad256-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2","volume":"35","author":"Dittmar","year":"2021","journal-title":"Cell Rep"},{"key":"2023092920103428000_pgad256-B16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152606776056698","article-title":"Nucleoside analog inhibitors of hepatitis C virus replication","volume":"6","author":"Carroll","year":"2006","journal-title":"Infect Disord Drug Targets."},{"key":"2023092920103428000_pgad256-B17","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/AAC.00498-08","article-title":"Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance","volume":"52","author":"Mathy","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092920103428000_pgad256-B18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"Schultz","year":"2022","journal-title":"Nature"},{"key":"2023092920103428000_pgad256-B19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227104","article-title":"Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus","volume":"15","author":"Good","year":"2020","journal-title":"PLoS One"},{"key":"2023092920103428000_pgad256-B20","first-page":"43","article-title":"Current methods for quantifying drug synergism","volume":"1","author":"Ma","year":"2019","journal-title":"Proteom Bioinform"},{"key":"2023092920103428000_pgad256-B21","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28527","article-title":"Inhibition of PIKFYVE kinase interferes ESCRT pathway to suppress RNA virus replication","volume":"95","author":"Luo","year":"2023","journal-title":"J Med Virol."},{"key":"2023092920103428000_pgad256-B22","author":"Sommadossi"},{"key":"2023092920103428000_pgad256-B23","first-page":"726A","volume-title":"Hepatology","author":"Afdhal","year":"2004"},{"key":"2023092920103428000_pgad256-B24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1081\/NCN-200060112","article-title":"Nm 283, an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine","volume":"24","author":"Pierra","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2023092920103428000_pgad256-B25","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1016\/S0168-8278(20)31210-1","article-title":"THU438\u2014a combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects","volume":"73","author":"Mungur","year":"2020","journal-title":"J Hepatol."},{"key":"2023092920103428000_pgad256-B26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol."}],"container-title":["PNAS Nexus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pnasnexus\/advance-article-pdf\/doi\/10.1093\/pnasnexus\/pgad256\/51035385\/pgad256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/2\/9\/pgad256\/51799649\/pgad256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/2\/9\/pgad256\/51799649\/pgad256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T20:46:38Z","timestamp":1696020398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article\/doi\/10.1093\/pnasnexus\/pgad256\/7236805"}},"subtitle":[],"editor":[{"given":"Amalio","family":"Telenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/pnasnexus\/pgad256","relation":{},"ISSN":["2752-6542"],"issn-type":[{"value":"2752-6542","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,8,3]]},"article-number":"pgad256"}}